Dr Reddy's Labs shares fell 4% on March 1, trading at Rs 6,193.55 on the NSE.
The company is a defendant in a legal complaint filed in the US District Court for New Jersey. The complaint alleges Dr Reddy's 'improperly restrained competition' and maintained a monopoly for the cancer drug Revlimid.
It claims the Indian drugmaker improperly limited generic competition for Revlimid. The legal action is based on claims under the Federal Antitrust law, seeking damages and equitable relief.
Previous antitrust lawsuits in October and November 2022 also targeted Dr Reddy's Labs, relating to Revlimid, in different US District Courts. Revlimid's significance lies in being a major contributor to Dr Reddy's financial performance, serving as a high-margin growth booster in recent quarters.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.